FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109078237> ?p ?o ?g. }

• W2109078237 abstract "Abstract Background Tissue factor (TF), an initiator of blood coagulation, participates in cancer progression and metastasis. We recently found that inhibition of MAPK/ERK upregulated both full length TF (flTF) and soluble isoform TF (asTF) gene expression and cell-associated TF activity in breast cancer MDA-MB-231 cells. We explored the possible mechanisms, especially the possible interaction with EGFR and PI3K/Akt pathways. Methods A plasmid containing TF promoter −2174 ~ +128 plus luciferase reporter gene was introduced into MDA-MB-231 cells to evaluate TF promoter activity. In order to study the interaction of these pathways, ERK inhibitor (PD98059), PI3K inhibitors (LY294002, wortmannin), Akt inhibitor (A6730), and EGFR inhibitor (erlotinib) as well as the corresponding siRNAs were used to treat MDA-MB-231 cells, and ovarian cancer OVCAR-3 and SKOV-3 cells. Quantitative PCR and western blot were used to determine TF expression. One stage clotting assays were used to measure pro-coagulation activity of the MDA-MB-231 cells. Results We show that PI3K inhibitors LY294002, wortmannin and A6730 significantly inhibited TF promoter activity, and reduced TF mRNA and protein levels due to the inhibition of Akt phosphorylation. In contrast, ERK inhibitor PD98059 and ERK siRNA enhanced TF promoter activity by 2.5 fold and induced an increase in TF mRNA and protein levels in a dose dependent manner in these cells. The PI3K/Akt pathway was shown to be involved in PD98059-induced TF expression because the induction was inhibited by PI3K/Akt inhibitors. Most interestingly, the EGFR inhibitor erlotinib and EGFR siRNA also significantly suppressed PD98059- or ERK siRNA-induced TF promoter activity and TF protein expression. Similar results were found with ovarian cancer cells SKOV-3 and OVCAR-3. Furthermore, in MDA-MB-231, mRNA levels of asTF were regulated in a similar way to that of TF in response to the cell treatment. Conclusions This study showed a regulatory mechanism in which MAPK/ERK signals inhibit EGFR/PI3K/Akt-mediated TF expression in breast cancer MDA-MB-231 cells. The same regulation was observed in ovarian cancer OVCAR-3 and SKOV-3 cells. Interestingly, we observed that both flTF and asTF could be regulated in a parallel manner in MDA-MB-231. As the PI3K/Akt pathway and EGFR regulate TF expression in cancer cells, targeting these signaling components is expected to potentially inhibit TF expression-associated tumor progression." @default.
• W2109078237 created "2016-06-24" @default.
• W2109078237 creator A5014068004 @default.
• W2109078237 creator A5015078046 @default.
• W2109078237 creator A5026162865 @default.
• W2109078237 creator A5035831472 @default.
• W2109078237 creator A5064692320 @default.
• W2109078237 creator A5067295942 @default.
• W2109078237 creator A5072610830 @default.
• W2109078237 creator A5083598955 @default.
• W2109078237 date "2012-04-25" @default.
• W2109078237 modified "2023-10-18" @default.
• W2109078237 title "Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells" @default.
• W2109078237 cites W1486093591 @default.
• W2109078237 cites W175200875 @default.
• W2109078237 cites W1752845679 @default.
• W2109078237 cites W1832657260 @default.
• W2109078237 cites W1995387334 @default.
• W2109078237 cites W2002016056 @default.
• W2109078237 cites W2003714769 @default.
• W2109078237 cites W2009644972 @default.
• W2109078237 cites W2019460216 @default.
• W2109078237 cites W2022035044 @default.
• W2109078237 cites W2029738976 @default.
• W2109078237 cites W2037900655 @default.
• W2109078237 cites W2040790582 @default.
• W2109078237 cites W2053668040 @default.
• W2109078237 cites W2057809694 @default.
• W2109078237 cites W2058157135 @default.
• W2109078237 cites W2060055959 @default.
• W2109078237 cites W2067011387 @default.
• W2109078237 cites W2071739144 @default.
• W2109078237 cites W2080431629 @default.
• W2109078237 cites W2081673273 @default.
• W2109078237 cites W2087032216 @default.
• W2109078237 cites W2092583562 @default.
• W2109078237 cites W2094458559 @default.
• W2109078237 cites W2110985695 @default.
• W2109078237 cites W2129594822 @default.
• W2109078237 cites W2137907878 @default.
• W2109078237 cites W2146933358 @default.
• W2109078237 cites W2168129192 @default.
• W2109078237 cites W2169872632 @default.
• W2109078237 cites W2315818202 @default.
• W2109078237 doi "https://doi.org/10.1186/1756-8722-5-16" @default.
• W2109078237 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3394220" @default.
• W2109078237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22534171" @default.
• W2109078237 hasPublicationYear "2012" @default.
• W2109078237 type Work @default.
• W2109078237 sameAs 2109078237 @default.
• W2109078237 citedByCount "50" @default.
• W2109078237 countsByYear W21090782372012 @default.
• W2109078237 countsByYear W21090782372013 @default.
• W2109078237 countsByYear W21090782372014 @default.
• W2109078237 countsByYear W21090782372015 @default.
• W2109078237 countsByYear W21090782372016 @default.
• W2109078237 countsByYear W21090782372017 @default.
• W2109078237 countsByYear W21090782372018 @default.
• W2109078237 countsByYear W21090782372019 @default.
• W2109078237 countsByYear W21090782372020 @default.
• W2109078237 countsByYear W21090782372021 @default.
• W2109078237 countsByYear W21090782372022 @default.
• W2109078237 countsByYear W21090782372023 @default.
• W2109078237 crossrefType "journal-article" @default.
• W2109078237 hasAuthorship W2109078237A5014068004 @default.
• W2109078237 hasAuthorship W2109078237A5015078046 @default.
• W2109078237 hasAuthorship W2109078237A5026162865 @default.
• W2109078237 hasAuthorship W2109078237A5035831472 @default.
• W2109078237 hasAuthorship W2109078237A5064692320 @default.
• W2109078237 hasAuthorship W2109078237A5067295942 @default.
• W2109078237 hasAuthorship W2109078237A5072610830 @default.
• W2109078237 hasAuthorship W2109078237A5083598955 @default.
• W2109078237 hasBestOaLocation W21090782371 @default.
• W2109078237 hasConcept C117262875 @default.
• W2109078237 hasConcept C126322002 @default.
• W2109078237 hasConcept C1491633281 @default.
• W2109078237 hasConcept C153911025 @default.
• W2109078237 hasConcept C185592680 @default.
• W2109078237 hasConcept C186738567 @default.
• W2109078237 hasConcept C22615655 @default.
• W2109078237 hasConcept C2776912716 @default.
• W2109078237 hasConcept C2778308172 @default.
• W2109078237 hasConcept C2778382381 @default.
• W2109078237 hasConcept C502942594 @default.
• W2109078237 hasConcept C54009773 @default.
• W2109078237 hasConcept C54355233 @default.
• W2109078237 hasConcept C55493867 @default.
• W2109078237 hasConcept C57074206 @default.
• W2109078237 hasConcept C62478195 @default.
• W2109078237 hasConcept C71924100 @default.
• W2109078237 hasConcept C75217442 @default.
• W2109078237 hasConcept C81885089 @default.
• W2109078237 hasConcept C86554907 @default.
• W2109078237 hasConcept C86803240 @default.
• W2109078237 hasConcept C95444343 @default.
• W2109078237 hasConceptScore W2109078237C117262875 @default.
• W2109078237 hasConceptScore W2109078237C126322002 @default.
• W2109078237 hasConceptScore W2109078237C1491633281 @default.
• W2109078237 hasConceptScore W2109078237C153911025 @default.
• W2109078237 hasConceptScore W2109078237C185592680 @default.

• next